News

Public · Published

Wells Fargo maintains CRISPR Therapeutics at Equal-Weight, lowers price target to $70 from $75

Wells Fargo kept its Equal-Weight rating on CRISPR Therapeutics but lowered its price target to $70 from $75, a 6.7% decrease. The revised target implies 40.0% upside from the November 3 closing price of $49.99.

Published:

Updated:

What happened

Wells Fargo kept its Equal-Weight rating on CRISPR Therapeutics but lowered its price target to $70 from $75, a 6.7% decrease. The revised target implies 40.0% upside from the November 3 closing price of $49.99.

Confirmed

Global impact / market context

The lower target signals that Wells Fargo sees less potential value than before, while keeping its rating unchanged. The target is an analyst estimate, not a guaranteed share price, and the article gives no explanation for the reduction or evidence of a change in the company’s business.

Analyst inference

The $70 target remains above the cited $49.99 closing price, so the analyst’s estimate still points to possible gains despite the cut. That gap reflects Wells Fargo’s view at the time, not a forecast shared by all analysts or a measure of future results.

Analyst inference

What to watch

  1. Look for any later Wells Fargo update to its rating or target; another revision could show whether the analyst’s view continues to change. Analyst inference
  2. Compare future CRISPR Therapeutics company updates with the reasons Wells Fargo gives, if any, for changing its target or rating. Analyst inference
  3. Watch whether the share price moves toward or away from the $70 target; the article does not report subsequent trading or investor reaction. Analyst inference

Evidence

  • Original source link unavailable